Lonza and Celladon Corporation Establish a Strategic Commercial Manufacturing Collaboration for Mydicar
Lonza and Celladon Corp. have entered into an agreement providing for the future commercial production of Mydicar (AAV1/SERCA2a), Celladon’s enzyme replacement therapy for advanced heart failure that is currently in Phase IIb clinical development.
This agreement follows a successful multiyear clinical manufacturing relationship and provides for initiation of preconstruction activities and the reservation of Lonza resources giving Celladon an opportunity to trigger construction of the dedicated facility and secure a long-term commercial supply arrangement. The establishment of this facility construction and commercial supply agreement provides Celladon with a strategic path to commercial supply, including plans for a dedicated cGMP production train within a new, state-of-the-art viral therapy facility.
In the near term, Lonza will complete a detailed engineering design for the facility to be located in Portsmouth, NH (USA). The facility will be separate from Lonza’s existing clinical and commercial mammalian operations facility also located in Portsmouth. In exchange for a reservation fee, Celladon has the option to trigger construction of the facility with a multiyear commitment to Lonza for the supply of Mydicar. Upon the trigger, Lonza will purchase from Celladon shares of Celladon common stock valued at $10 million.
Upon completion of the new manufacturing facility, Lonza is to transfer Celladon’s 2000 L commercial-scale process from Lonza’s facility in Houston, TX (USA) to the new facility in Portsmouth. Process validation is expected to be completed in the new Portsmouth facility.
“This strategic collaboration for Celladon’s cGMP production and future expansion of our viral therapy manufacturing capabilities is an exciting endeavor for Lonza,” said Marc Funk, COO, Lonza’s Pharma & Biotech segment. “This extended partnership continues to reflect Lonza’s track record as a trusted partner for the scale-up of emerging technologies in preparation for commercial launch. We are committed to the commercial manufacturing market and to the advancement of potentially life-saving treatments like Mydicar.”
“Our previous multi-year relationship with Lonza has helped us rapidly advance the clinical manufacture of MYDICAR,” said Krisztina Zsebo, Ph.D., Chief Executive Officer at Celladon. “As we continue to progress the development of MYDICAR®, we are pleased to announce this expansion of our partnership with Lonza in support of future commercial supply.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance